Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.

Clara Martinez-VilaF A MorenoM M EstébanezG R AresG VillacampaP DashtiH S OberoiR Martin-HuertasP JaresL AlosC TeixidoR RullM SanchezJ MalvehyE CarceleroI ValduviecoA A Fernandez

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)

Overall survival of real-world patients from our cohort receiving ipilimumab plus nivolumab was lower than in previous studies. The ECOG score, LDH values, the presence of liver metastases and the NLR were independent prognostic factors for survival.

Keyphrases

prognostic factors
liver metastases
end stage renal disease
chronic kidney disease
ejection fraction
patient reported outcomes
case control